ATS Reports Third Quarter Fiscal 2025 Results
1. ATS Q3 revenue declined 13.3% year-over-year to $652 million. 2. Net income fell 86.2% year-over-year, indicating significant challenges. 3. Order Bookings increased 32.2% year-over-year, reaching $883 million. 4. Life sciences segment revenue up 18.7%, showcasing growth potential. 5. Outstanding overdue accounts receivable from an EV customer total $165 million.